drug

Transcranial Magnetic Stimulation (TMS)

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
DEVICE
Pre-approval / investigational in the US
Developed by Yale University
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
DEVICE

Indications

Trials

2
Models of Auditory Hallucination
NCT04210557—Terminated
Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)
NCT00517075Phase 2Terminated

KOLs & investigators

2
Philip R Corlett, PhD
Arielle D. Stanford, MD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Yale University
company
trial
Models of Auditory Hallucination
NA
trial
Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)
PHASE2
trial
indication
Schizophrenia
indication
Schizo Affective Disorder
indication
Auditory Hallucination
indication
Schizophrenia
indication
KOL
Philip R Corlett, PhD
KOL score —
person
Arielle D. Stanford, MD
KOL score —
person